Tags

Type your tag names separated by a space and hit enter

MP29-02: a breakthrough for the treatment of allergic rhinitis.
Expert Opin Pharmacother. 2013 Oct; 14(15):2101-13.EO

Abstract

INTRODUCTION

Allergic rhinitis (AR) can be challenging to treat. For many patients, current therapies (including multiple therapies) provide insufficient symptom relief. There is, therefore, a clear unmet medical need for a new and more effective AR treatment option. MP29-02 (Dymista) is a novel intranasal formulation of azelastine hydrochloride and fluticasone propionate in an advanced delivery system.

AREAS COVERED

The goal of this article is to review all MP29-02 clinical data currently published with a view to establish its potential to fill the current unmet medical need in AR. Relevant articles and abstracts were reviewed from PUBMED and conference proceedings.

EXPERT OPINION

MP29-02 represents a breakthrough in AR management for the following reasons: i) MP29-02 has been extensively studied in comparison to first-line therapies in both seasonal AR (SAR) patients and in those with chronic rhinitis (i.e., perennial allergic rhinitis [PAR] and nonallergic (vasomotor) rhinitis) in one of the largest direct head-to-head clinical trial programmes in AR, to date. ii) With MP29-02, the efficacy of an intranasal corticosteroid (INS), the first-line choice for AR has been exceeded for the first time without safety repercussions. AR patients treated with MP29-02 experience significantly greater relief from their overall nasal and ocular symptoms compared to two first-line AR therapies, irrespective of season, symptom type, or disease severity. More patients treated with MP29-02 achieve a substantial reduction (i.e., 50% reduction) in their symptoms and also complete symptom relief and achieve these clinically relevant responses days faster than an INS or antihistamine. iii) Formulation of a topical medication is critical, and MP29-02's novel formulation and/or its device contribute to its clinical efficacy.

Authors+Show Affiliations

University of Cincinnati College of Medicine, Department of Internal Medicine , 3255 Eden Avenue ML#563, Suite 350, Cincinnati, OH 45267-0563 , USA +1 513 558 5533 ; +1 513 558 3799 ; jonathan.bernstein@uc.edu.

Pub Type(s)

Journal Article
Research Support, Non-U.S. Gov't
Review

Language

eng

PubMed ID

23977840

Citation

Bernstein, Jonathan A.. "MP29-02: a Breakthrough for the Treatment of Allergic Rhinitis." Expert Opinion On Pharmacotherapy, vol. 14, no. 15, 2013, pp. 2101-13.
Bernstein JA. MP29-02: a breakthrough for the treatment of allergic rhinitis. Expert Opin Pharmacother. 2013;14(15):2101-13.
Bernstein, J. A. (2013). MP29-02: a breakthrough for the treatment of allergic rhinitis. Expert Opinion On Pharmacotherapy, 14(15), 2101-13. https://doi.org/10.1517/14656566.2013.828693
Bernstein JA. MP29-02: a Breakthrough for the Treatment of Allergic Rhinitis. Expert Opin Pharmacother. 2013;14(15):2101-13. PubMed PMID: 23977840.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - MP29-02: a breakthrough for the treatment of allergic rhinitis. A1 - Bernstein,Jonathan A, Y1 - 2013/08/26/ PY - 2013/8/28/entrez PY - 2013/8/28/pubmed PY - 2014/4/4/medline SP - 2101 EP - 13 JF - Expert opinion on pharmacotherapy JO - Expert Opin Pharmacother VL - 14 IS - 15 N2 - INTRODUCTION: Allergic rhinitis (AR) can be challenging to treat. For many patients, current therapies (including multiple therapies) provide insufficient symptom relief. There is, therefore, a clear unmet medical need for a new and more effective AR treatment option. MP29-02 (Dymista) is a novel intranasal formulation of azelastine hydrochloride and fluticasone propionate in an advanced delivery system. AREAS COVERED: The goal of this article is to review all MP29-02 clinical data currently published with a view to establish its potential to fill the current unmet medical need in AR. Relevant articles and abstracts were reviewed from PUBMED and conference proceedings. EXPERT OPINION: MP29-02 represents a breakthrough in AR management for the following reasons: i) MP29-02 has been extensively studied in comparison to first-line therapies in both seasonal AR (SAR) patients and in those with chronic rhinitis (i.e., perennial allergic rhinitis [PAR] and nonallergic (vasomotor) rhinitis) in one of the largest direct head-to-head clinical trial programmes in AR, to date. ii) With MP29-02, the efficacy of an intranasal corticosteroid (INS), the first-line choice for AR has been exceeded for the first time without safety repercussions. AR patients treated with MP29-02 experience significantly greater relief from their overall nasal and ocular symptoms compared to two first-line AR therapies, irrespective of season, symptom type, or disease severity. More patients treated with MP29-02 achieve a substantial reduction (i.e., 50% reduction) in their symptoms and also complete symptom relief and achieve these clinically relevant responses days faster than an INS or antihistamine. iii) Formulation of a topical medication is critical, and MP29-02's novel formulation and/or its device contribute to its clinical efficacy. SN - 1744-7666 UR - https://www.unboundmedicine.com/medline/citation/23977840/MP29_02:_a_breakthrough_for_the_treatment_of_allergic_rhinitis_ L2 - https://www.tandfonline.com/doi/full/10.1517/14656566.2013.828693 DB - PRIME DP - Unbound Medicine ER -